1. Home
  2. TSHA vs PLPC Comparison

TSHA vs PLPC Comparison

Compare TSHA & PLPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TSHA
  • PLPC
  • Stock Information
  • Founded
  • TSHA 2019
  • PLPC 1947
  • Country
  • TSHA United States
  • PLPC United States
  • Employees
  • TSHA N/A
  • PLPC N/A
  • Industry
  • TSHA Biotechnology: Pharmaceutical Preparations
  • PLPC Water Sewer Pipeline Comm & Power Line Construction
  • Sector
  • TSHA Health Care
  • PLPC Industrials
  • Exchange
  • TSHA Nasdaq
  • PLPC Nasdaq
  • Market Cap
  • TSHA 728.4M
  • PLPC 789.5M
  • IPO Year
  • TSHA 2020
  • PLPC N/A
  • Fundamental
  • Price
  • TSHA $3.02
  • PLPC $200.37
  • Analyst Decision
  • TSHA Strong Buy
  • PLPC
  • Analyst Count
  • TSHA 7
  • PLPC 0
  • Target Price
  • TSHA $8.71
  • PLPC N/A
  • AVG Volume (30 Days)
  • TSHA 3.5M
  • PLPC 59.8K
  • Earning Date
  • TSHA 11-12-2025
  • PLPC 10-29-2025
  • Dividend Yield
  • TSHA N/A
  • PLPC 0.40%
  • EPS Growth
  • TSHA N/A
  • PLPC 5.07
  • EPS
  • TSHA N/A
  • PLPC 8.56
  • Revenue
  • TSHA $8,098,000.00
  • PLPC $632,231,000.00
  • Revenue This Year
  • TSHA N/A
  • PLPC N/A
  • Revenue Next Year
  • TSHA N/A
  • PLPC N/A
  • P/E Ratio
  • TSHA N/A
  • PLPC $23.21
  • Revenue Growth
  • TSHA N/A
  • PLPC 7.95
  • 52 Week Low
  • TSHA $1.05
  • PLPC $115.30
  • 52 Week High
  • TSHA $3.40
  • PLPC $203.00
  • Technical
  • Relative Strength Index (RSI)
  • TSHA 51.14
  • PLPC 68.13
  • Support Level
  • TSHA $3.16
  • PLPC $186.12
  • Resistance Level
  • TSHA $2.99
  • PLPC $199.27
  • Average True Range (ATR)
  • TSHA 0.18
  • PLPC 5.41
  • MACD
  • TSHA -0.01
  • PLPC -0.25
  • Stochastic Oscillator
  • TSHA 38.21
  • PLPC 84.42

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

About PLPC Preformed Line Products Company

Preformed Line Products Co is a designer and manufacturer of products and systems for constructing and maintaining overhead and underground networks for energy, telecommunication, cable operators, data communication, and other industries. In addition, it provides solar hardware systems and mounting hardware for a variety of solar power applications. Its products consist of Energy Products, Communications Products, and Special Industries Products. The company's majority of the revenue is derived from the sale of products in The Americas with operations also in PLP-USA, Europe, the Middle East and Africa, and Asia-Pacific. The revenue gets driven by Energy products which comprise protecting transmission conductors, spacers, spacer-dampers, and Stockbridge dampers.

Share on Social Networks: